Publications by authors named "D Tihanyi"

Landiolol, a highly cardioselective agent with a short half-life (2.4-4 min), is commonly used as a perfusor or bolus application to treat tachycardic arrhythmia. Some small studies suggest that prior oral β-blocker use results in a less effective response to intravenous β-blockers.

View Article and Find Full Text PDF

Machine perfusion (MP) is often referred to as one of the most promising advancements in liver transplantation research of the last few decades, with various techniques and modalities being evaluated in preclinical studies using animal models. However, low scientific rigor and subpar reporting standards lead to limited reproducibility and translational potential, hindering progress. This pre-registered systematic review (PROSPERO: CRD42021234667) aimed to provide a thematic overview of the preclinical research landscape on MP in liver transplantation using in vivo transplantation models and to explore methodological and reporting standards, using the ARRIVE (Animal Research: Reporting of In Vivo Experiments) score.

View Article and Find Full Text PDF

Lifestyle choices and consumption play a large role in contributing to per capita greenhouse gas emissions. Certain activities, like fossil fuel ground transportation, long-haul flights, diets with animal products and residential heating and cooling contribute significantly to per capita emissions. There is uncertainty around whether literacy about these actions encourages individuals to act pro-environmentally to reduce personal carbon footprints or to prioritize the most effective actions.

View Article and Find Full Text PDF
Article Synopsis
  • Landiolol, a β1-selective beta-blocker, shows potential for rate control in critically ill patients with non-compensatory tachycardia, though its bolus formulation lacks extensive efficacy and safety data.
  • A study on 30 patients revealed that 41% achieved successful heart rate control, with a significant reduction in average heart rate post-application, although blood pressure changes were clinically insignificant.
  • Overall, the administration of push-dose Landiolol was found to be safe and effective, with no serious adverse events reported.
View Article and Find Full Text PDF